Singapore markets closed

Johnson & Johnson (JNJ)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
176.59-0.61 (-0.34%)
As of 03:09PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close177.20
Bid176.42 x 1000
Ask176.43 x 900
Day's range176.31 - 177.89
52-week range155.72 - 186.69
Avg. volume7,065,304
Market cap461.691B
Beta (5Y monthly)0.57
PE ratio (TTM)24.59
Earnings dateN/A
Forward dividend & yield4.52 (2.55%)
Ex-dividend date21 Nov 2022
1y target estN/A
  • Business Wire

    Johnson & Johnson to Participate in the 41st Annual J.P. Morgan Healthcare Conference

    NEW BRUNSWICK, N.J., December 07, 2022--Johnson & Johnson (NYSE: JNJ) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman Elect of the Board and Chief Executive Officer will represent the Company in a session scheduled at 12:45 p.m. (Eastern Time).

  • Business Wire

    Johnson & Johnson Names CEO Joaquin Duato as Chairman of the Board

    NEW BRUNSWICK, N.J., November 30, 2022--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has elected Chief Executive Officer, Mr. Joaquin Duato, to assume the additional position of Chairman, effective in January 2023. Mr. Duato succeeds Mr. Alex Gorsky, who will step down from his role as Executive Chairman following a brief transitional period.

  • Business Wire

    Johnson & Johnson to Acquire Abiomed

    NEW BRUNSWICK, N.J. & DANVERS, Mass., November 01, 2022--Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, and Abiomed (NASDAQ: ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender offer all outstanding shares of Abiomed, for an upfront payment of $380.00 per share in cash, corresponding to an